Genmab
↗Copenhagen, Denmark
Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer and other serious diseases. The company has developed several proprietary technologies, including the DuoBody platform for bispecific antibodies and the HexaBody platform for enhancing antibody effector functions.
Genmab has a highly successful track record of partnerships with major pharmaceutical companies, resulting in several blockbuster products. Their business model focuses on high-value R&D while leveraging partners like Janssen (J&J), AbbVie, and Pfizer for large-scale commercialization and late-stage development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$2.4B
Founded:1999
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$1.2B
Investors:BlackRock, Fidelity, Wellington Management, Novo Holdings
STOCK
Exchange:NASDAQ
Ticker:GMAB
Market Cap:$16.5B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:mAb, Bispecific Antibody, ADC, HexaBody
Active Trials:45
Trial Phases:Phase 1: 18 | Phase 2: 15 | Phase 3: 10 | Phase 4: 2
FDA Approvals:8
EMA Approvals:7
CORPORATE STRUCTURE
Subsidiaries:Genmab US, Inc., Genmab B.V. (Netherlands), Genmab K.K. (Japan)
Key Partnerships:Janssen (J&J) - Darzalex, Rybrevant, Tecvayli, AbbVie - Epcoritamab (Epkinly), Pfizer (formerly Seagen) - Tivdak, BioNTech - DuoBody-CD40x4-1BB
COMPETITION
Position:Leader
Competitors:Amgen, Roche (Genentech), Regeneron, AstraZeneca, Pfizer
LEADERSHIP
Key Executives:
Jan van de Winkel - CEO
Anthony Pagano - CFO
Scientific Founders:Jan van de Winkel, Florian Schönharting
Board Members:Deirdre P. Connelly (Chair), Pernille Erenbjerg, Rolf Hoffmann
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Genmab and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Genmab. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.